Cargando…

Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction

SIMPLE SUMMARY: Despite the relationship between Carfilzomib (CFZ) therapy in multiple myeloma (MM) and cardiovascular adverse events (CVAEs), no specific validated protocols on cardiovascular risk assessment are available. In this prospective study, we investigated major predictors of CVAEs prior t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Astarita, Anna, Mingrone, Giulia, Airale, Lorenzo, Vallelonga, Fabrizio, Covella, Michele, Catarinella, Cinzia, Cesareo, Marco, Bruno, Giulia, Leone, Dario, Giordana, Carlo, Cetani, Giusy, Salvini, Marco, Gay, Francesca, Bringhen, Sara, Rabbia, Franco, Veglio, Franco, Milan, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036868/ https://www.ncbi.nlm.nih.gov/pubmed/33915804 http://dx.doi.org/10.3390/cancers13071631

Ejemplares similares

Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients
por: Mingrone, Giulia, et al.
Publicado: (2021)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience
por: Mingrone, Giulia, et al.
Publicado: (2023)

Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy
por: Bruno, Giulia, et al.
Publicado: (2019)

Cardiovascular Hypertension-Mediated Organ Damage in Hypertensive Urgencies and Hypertensive Outpatients
por: Vallelonga, Fabrizio, et al.
Publicado: (2022)

A Novel Approach to Left Ventricular Filling Pressure Assessment: The Role of Hemodynamic Forces Analysis
por: Airale, Lorenzo, et al.
Publicado: (2021)

Accuracy of a Symptom-Based Approach to Identify Hypertensive Emergencies in the Emergency Department
por: Vallelonga, Fabrizio, et al.
Publicado: (2020)

Moving Toward Continuous Therapy in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Targeted treatments for multiple myeloma: specific role of carfilzomib
por: Sugumar, Dhivya, et al.
Publicado: (2015)

Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells
por: Baranowska, Katarzyna, et al.
Publicado: (2016)

Carfilzomib boosted combination therapy for relapsed multiple myeloma
por: Steiner, Raphael E, et al.
Publicado: (2017)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
por: Méndez-Toro, Arnold, et al.
Publicado: (2020)

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma
por: Yang, Jenny Z., et al.
Publicado: (2021)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Central Pressure Appraisal: Clinical Validation of a Subject-Specific Mathematical Model
por: Tosello, Francesco, et al.
Publicado: (2016)

Correction: Central Pressure Appraisal: Clinical Validation of a Subject-Specific Mathematical Model
por: Tosello, Francesco, et al.
Publicado: (2016)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Introduction to Hemodynamic Forces Analysis: Moving Into the New Frontier of Cardiac Deformation Analysis
por: Vallelonga, Fabrizio, et al.
Publicado: (2021)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
por: Fostier, Karel, et al.
Publicado: (2012)

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
por: Badros, A Z, et al.
Publicado: (2013)

Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib
por: Liberman, Vladimir, et al.
Publicado: (2016)

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017)

Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma
por: Ikoma, Takenori, et al.
Publicado: (2019)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
por: Capra, Marcelo, et al.
Publicado: (2021)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka, Ajay, et al.
Publicado: (2013)

Characterization of the Molecular Mechanism of the Bone-Anabolic Activity of Carfilzomib in Multiple Myeloma
por: Hu, Bo, et al.
Publicado: (2013)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
por: Mele, Giuseppe, et al.
Publicado: (2018)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani, Divaya, et al.
Publicado: (2017)

Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration
por: Nabissi, Massimo, et al.
Publicado: (2016)

Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma
por: Saburi, Masuho, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j633qv46gajstnrb4ngpe9dl1c